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Figure 1 Centripetal obesity and wide and divergent 
purpuric striae.
SUMMARY
Inhaled corticosteroids are generally considered safe 
and do not usually lead to systemic adverse events since 
their plasma concentrations are low due to hepatic 
metabolism by the cytochrome P450 3A4. However, 
when associated with inhibitors of this cytochrome, 
such as ritonavir, they may lead to iatrogenic 
Cushing syndrome by the systemic accumulation of 
corticosteroids and consequent suppression of the 
hypothalamic- pituitary- adrenal axis. We present a 
case of iatrogenic Cushing syndrome complicated by 
multifocal osteonecrosis in a patient with HIV infection 
on antiretroviral therapy with protease inhibitors 
boosted with ritonavir, after the association of inhaled 
fluticasone. This clinical case highlights a relevant 
interaction between corticosteroids and inhibitors of 
the cytochrome P450 and the severe consequences that 
may occur.
BACkgRoUnd
Ritonavir is a protease inhibitor that is often used in 
combination with other antiretrovirals in the treat-
ment of HIV infection. It is a potent inhibitor of the 
hepatic cytochrome P450 3A4 (CYP3A4) acting as 
a booster and allowing other antiretroviral agents 
metabolised by this cytochrome to reach higher 
plasma concentrations. This enables a decrease in 
pill burden and an increase of the dosing intervals, 
improving patient adherence and decreasing treat-
ment failure.1
Inhaled corticosteroids are drugs widely used 
in the treatment of asthma, allergic rhinitis and 
chronic obstructive pulmonary disease (COPD). 
They are considered safe due to the low plasma 
concentrations they reach after metabolism by the 
CYP3A4. When combined with potent inhibitors of 
this cytochrome, there may be a significant increase 
in plasma corticosteroid levels.1 This may cause 
iatrogenic Cushing syndrome, suppression of the 
hypothalamic–pituitary–adrenal (HPA) axis, acute 
adrenal insufficiency in case of abrupt corticoste-
roid withdrawal, as well as hypertension, osteopo-
rosis and avascular necrosis.1–5
We report a case of iatrogenic Cushing syndrome 
and multifocal osteonecrosis in a patient with 
HIV1 infection on a ritonavir- boosted antiretro-
viral therapy (ART) and COPD treated with fluti-
casone. It is intended to emphasise the importance 
of the interaction between inhaled corticosteroids 
and cytochrome P450 (CYP450) inhibitors and its 
potential severe consequences.
CASe pReSenTATion
A 40- year- old man with well- controlled HIV1 
infection (CD4+ T cell count of 518 cells/mm3 
and undetectable HIV1 RNA) presented to the 
Endocrinology Department due to weight gain 
and abdominal and limb striae. His medical back-
ground included COPD and alcohol, tobacco and 
past intravenous heroin abuse. HIV1 infection was 
diagnosed when he was 25 years old and treatment 
with lopinavir/ritonavir 400 mg/100 mg two times 
per day, saquinavir 1000 mg two times per day 
and tenofovir 300 mg one time a day was started 
at the age of 33 years (CD4+ T cell count of 78 
cells/mm3 and HIV1 RNA viral load of 2300 copies, 
log10 3.38, before ART). At 35 years of age inhaled 
therapy with fluticasone/salmeterol 250 µg/50 µg 
two times per day and tiotropium bromide 18 µg 
one time a day was added for COPD. One year 
later, he developed avascular necrosis of the right 
femoral head and underwent total hip arthroplasty.
The patient was first observed in January 2013, 
5 years after the initiation of inhaled corticosteroid 
therapy. He reported a gradual increase in abdom-
inal and cervical volume, 15 kg weight gain over the 
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Table 1 Laboratory findings evolution
normal range
With corticosteroids Without corticosteroids (since Jul 2013)
January 2013,















0–46 <5 <5 10.5 21.4 16 17.9 26.4
Serum cortisol
(μg/dL)
4.3–23 0.4 0.4 2.6 12.2 9.1 10.4 20.5
Urinary cortisol
(μg/24 hours)
55.5–286 10 9 13 84 194
FSH (U/L) 1.4–18.1 36.6 26.3 25.0 27.2 30.0
LH (U/L) 1.5–9.3 12.7 12.7 13.7 15.9 13.0
Total testosterone
(ng/dL)
240–830 465 309 290 337
Free testosterone
(pg/mL)
6.6–23 2.0 5.4 5.1 5.6 9.3
SHBG
(nmol/L)
10–57 64.2 67.6 54.9 69.0
*At this time the diagnosis of exogenous Cushing syndrome was made, and the patient started reducing the dose of corticosteroids.
ACTH, adrenocorticotropic hormone; FSH, follicle- stimulating hormone; LH, luteinising hormone; SHBG, sexhormone- binding globulin.
previous 6 months, appearance of abdominal and limb striae, 
gynecomastia, ankle oedema, erectile dysfunction and humoral 
lability. On physical examination he was noted to have a plethoric 
‘full moon’ facies, centripetal obesity (body mass index (BMI) of 
35 kg/m2), dorsocervical fat pads, proximal muscular atrophy, 
wide and divergent purpuric striae in the abdomen, arms and 
thighs (figure 1) and high blood pressure.
inveSTigATionS
Laboratory evaluation revealed low serum and urinary cortisol 
with low serum adrenocorticotrophic hormone (ACTH) concen-
trations, indicating suppression of the HPA axis. Furthermore, 
dyslipidaemia and hypergonadotropic hypogonadism were 
detected (table 1). A bone density scan (BDS) revealed low bone 
mineral density (Z- score of the lumbar spine of −3.6), compat-
ible with osteoporosis.
diFFeRenTiAl diAgnoSiS
Presented with these findings, a diagnosis of exogenous/iatro-
genic Cushing syndrome secondary to inhaled fluticasone was 
made.
Regarding the differential diagnosis of Cushing syndrome in 
patients undergoing ART, it is important to consider ART- related 
lipodystrophy. In lipodystrophy, there is a metabolic dysregula-
tion that leads to weight gain, central fat distribution and dors-
ocervical fat pads. In the case at hand, the presence of rapid 
weight gain, purpuric abdominal striae and facial plethora all 
point to the Cushing syndrome. In contrast, HIV- associated lipo-
dystrophy is associated with more evident peripheral muscular 
atrophy than Cushing syndrome.1–3 Laboratory evaluation clar-
ifies the diagnosis since there are abnormal concentrations of 
cortisol and ACTH in the Cushing syndrome.
We must also distinguish between iatrogenic and endogenous 
Cushing syndrome. When Cushing syndrome is iatrogenic, the 
endogenous synthesis of cortisol is supressed due to the negative 
feedback exerted by the excess of exogenous corticosteroids on 
the hypothalamus and the pituitary gland. Suppressed ACTH 
and cortisol concentrations mean that the source of corticoste-
roids is exogenous, representing therefore an iatrogenic Cushing 
syndrome. However, if the patient is taking hydrocortisone, the 
cortisol measurements do not distinguish whether the source of 
cortisol is endogenous or administered. Other corticosteroids 
may also interfere with these measurements.
TReATMenT
After the diagnosis, the dose of fluticasone was progressively 
reduced. The patient also started antihypertensive and statin 
therapy.
oUTCoMe And FolloW-Up
After 4 months of corticosteroids at a halved dose, the patient 
continued to demonstrate HPA axis suppression and the decision 
was made to continue weaning fluticasone. Eventually the fluti-
casone/salmeterol was totally ceased and replaced by indacaterol 
150 µg one time a day in July 2013.
In September 2013, after 3 months without corticosteroids, 
the patient had a less ‘full moon’ facies, no oedema, less purpuric 
striae and a 6 kg weight loss over a 9 month period (BMI of 33 kg/
m2). He reported an improvement of erectile dysfunction. From 
the respiratory point of view, the patient remained stable without 
the need of steroid therapy. Serum and urinary cortisol were 
closer to reference values and ACTH was not suppressed (table 1).
Approximately 1 year after corticosteroid cessation, the patient 
complained of left knee pain and claudication. Plain radiography 
of the knees revealed bilateral sclerotic lesions in a serpiginous 
pattern and the diagnosis of aseptic necrosis with subchondral 
bone collapse of the medial left femoral condyle was confirmed 
by magnetic resonance imaging (figure 2). Conservative treat-
ment that included protected weightbearing with crutches, non- 
steroidal anti- inflammatory drugs and alendronate 70 mg weekly 
for 2 years ensured full symptomatic relief and no radiographic 
progression on long- term follow- up.
There was a gradual improvement of the Cushing syndrome 
signs as well as laboratory abnormalities, with normalisation of 
the HPA axis function. Reassessment BDS revealed improvement 
of the bone mineral density. Laboratory tests performed at the 
same time revealed total testosterone and free testosterone levels 
within normal range, while maintaining high follicle- stimulating 
hormone and luteinising hormone(table 1).
diSCUSSion
The presented clinical case describes an iatrogenic Cushing 
syndrome complicated by multifocal osteonecrosis resulting 
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Figure 2 Resonance imaging of the left knee demonstrating aseptic 
necrosis with subchondral bone collapse of the medial left femoral 
condyle.
learning points
 ► Ritonavir is a potent cytochrome P450 3A4 inhibitor acting 
as a booster of other drugs metabolised via this cytochrome, 
such as corticosteroids.
 ► Co- administration of ritonavir (or other potent cytochrome 
P450 (CYP450) inhibitors) with corticosteroids, including 
intranasal or inhaled formulations, may induce systemic 
corticosteroid accumulation, Cushing syndrome, adrenal 
insufficiency, hypertension, osteoporosis and avascular 
necrosis.
 ► Compared with other inhaled corticosteroids, fluticasone 
is the most susceptible to drug interactions with CYP450 
inhibitors while beclomethasone is probably the safest 
option.
 ► Treatment options for the iatrogenic Cushing syndrome 
induced by this interaction include replacing ritonavir with 
another antiretroviral or slow tapering of fluticasone and 
replacing it with beclomethasone, a leukotriene antagonist or 
an anticholinergic agent.
from a drug interaction between ritonavir and fluticasone. There 
are already a number of published articles describing the conse-
quences of the interaction between these two drugs.3In 2013, 
a Review article found 51 published case reports regarding 
adverse effects with the use of inhaled or/and intranasal cortico-
steroids and protease inhibitors, most of which (approximately 
86%) were related to the association between fluticasone and 
ritonavir.3 The most common reported symptoms were ‘full 
moon’ facies, facial hirsutism, central obesity and weight gain, 
dorsocervical fat pads, striae and easy bruising.3 There were 
five cases of osteoporosis and one case of osteonecrosis of both 
hips.3 5 However, despite the presence of these well- documented 
cases of iatrogenic Cushing syndrome, similar reports continue 
to emerge.2 6 7
Ritonavir, being a potent inhibitor of the hepatic CYP3A4, 
increases the concentration of other protease inhibitors included 
in the combined ART and enhances HIV treatment success. 
However, ritonavir can also increase corticosteroids concen-
trations, as they are substrates of the CYP3A4. Therefore, this 
interaction can result in impaired metabolism and systemic 
corticosteroid accumulation, adrenal suppression and Cushing 
syndrome.1 2
Compared with other inhaled corticosteroids, fluticasone 
exhibits the most suppressive impact on the HPA axis. This is due 
to its pharmacokinetic properties, such as higher glucocorticoid 
receptor binding affinity, longer half- life and higher lipophilicity, 
allowing a greater volume of distribution. These characteristics 
facilitate the systemic accumulation of fluticasone and make it 
more susceptible to drug interactions.1–3
The most common clinical feature of the Cushing syndrome 
is weight gain with central fat distribution. Other typical mani-
festations include, ‘full moon’ facies, facial plethora, dorsocer-
vical fat pads (‘buffalo hump’), skin atrophy, acne, easy bruising 
and purple striae. Hirsutism (in women), proximal myopathy, 
insulin resistance, dyslipidaemia, hypertension, immunosup-
pression, psychiatric disorders and osteopenia or osteoporosis 
are also common.2 8 9 Given the reported clinical case, it is also 
important to note that hypogonadism, HIV infection, ART and 
tobacco and alcohol abuse may also contribute to a decrease in 
bone mineral density.10 11
There are other important consequences of hypercortisolism, 
namely gonadal dysfunction and aseptic osteonecrosis. Gonadal 
dysfunction occurs in more than 75% of patients with Cushing 
syndrome and is usually hypogonadotropic.9 11 However, the 
patient presented with hypergonadotropic hypogonadism and 
several contributing factors transpire: chronic alcoholism, the 
use of certain illicit drugs and HIV infection.11 12
As mentioned, the patient developed avascular necrosis of 
the right femoral head and, approximately 5 years after, of both 
knees. Although infrequent, avascular necrosis may have been 
the first manifestation of the Cushing syndrome.13 Multiple 
other risk factors for avascular necrosis were also present: alco-
holism, hypertriglyceridemia, HIV infection and smoking.4 5 13 
Therefore, we cannot conclude that hypercortisolism was an 
isolated cause of multifocal osteonecrosis, but it probably was 
a significant contributing factor. To our knowledge, only 
two other cases of avascular necrosis have been reported as 
being attributed to the interaction between fluticasone and 
ritonavir.4 5
After the diagnosis of iatrogenic Cushing syndrome due to the 
interaction between inhaled corticosteroids and ritonavir, treat-
ment involves either replacing ritonavir with another antiretro-
viral that does not inhibit the CYP3A4 or changing fluticasone 
while maintaining ritonavir. Fluticasone can be substituted for 
another less potent inhaled corticosteroid and less dependent 
on CYP450 metabolism (eg, beclomethasone), a leukotriene 
antagonist (eg, montelukast) or an anticholinergic agent (eg, 
tiotropium). It is unclear if significant dose reductions of the 
intranasal/inhaled corticosteroid will result in the complete reso-
lution of the clinical picture since accounts of this interaction 
have been reported at low doses.2 3
If treatment with another inhaled corticosteroid is started, the 
lowest possible dose should always be administered and the clin-
ical course should be closely monitored considering case reports 
of iatrogenic Cushing syndrome due to other inhaled cortico-
steroids.1 3
If corticosteroid therapy is to be suspended, this should always 
be done progressively because of the risk of acute adrenal insuf-
ficiency. The exogenous corticosteroids supress the HPA axis. 
With an abrupt cessation of exogenous corticosteroids, the HPA 
axis is incapable of rapidly producing endogenous cortisol, 
which results in acute adrenal insufficiency.6
In conclusion, corticosteroid therapy even in ‘non- systemic’ 
formulations, namely intranasal or inhaled, should be avoided 
in patients receiving ritonavir (or another CYP3A4 inhibitor). If 
treatment with an inhaled corticosteroid is imperative, flutica-
sone should not be the first therapeutic option.
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